Last reviewed · How we verify
Anti CD45 monoclonal antibody — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Anti CD45 monoclonal antibody (Anti CD45 monoclonal antibody) — Baylor College of Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti CD45 monoclonal antibody TARGET | Anti CD45 monoclonal antibody | Baylor College of Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti CD45 monoclonal antibody CI watch — RSS
- Anti CD45 monoclonal antibody CI watch — Atom
- Anti CD45 monoclonal antibody CI watch — JSON
- Anti CD45 monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). Anti CD45 monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd45-monoclonal-antibody. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab